Aspects of the thromboxane receptor system.

@article{Armstrong1995AspectsOT,
  title={Aspects of the thromboxane receptor system.},
  author={R. Armstrong and N. H. Wilson},
  journal={General pharmacology},
  year={1995},
  volume={26 3},
  pages={
          463-72
        }
}
1. The aim of this review is to establish what is known about the thromboxane (TP) receptor, and to identify where future research is headed. In addition, the impact of the recent advances at the molecular level on resolving pharmacological controversies, such as possible subtypes of the TP receptor, is discussed and what molecular information is known about the TP receptor presented. 2. The clinical status of TP receptor antagonists is considered particularly in relation to the potential role… Expand
Agents Acting on Prostanoid and Thromboxane Receptors
This chapter covers recent developments in the prostaglandin and thromboxane research area, with particular focus on the medicinal chemistry aspects. Each of the receptors is discussed in turn withExpand
The role of thromboxane A2 in complement activation-related pseudoallergy
TLDR
Animal experiments and recent clinical observations suggest that the cyclooxygenase blocker indomethacin may represent an effective new approach to prevent liposome-induced CARPA, lending clinical relevance to better understand the involvement of TXA2 and other eicosanoids in this adverse immune effect. Expand
Thromboxane prostanoid receptor in human airway smooth muscle cells: a relevant role in proliferation.
TLDR
It is reported that the presence of mRNA for both alpha and beta isoforms of the thromboxane A(2) receptor in smooth muscle cells from human bronchi correlates with protein expression evaluated by radioligand binding of the antagonist, SQ29,548. Expand
Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology.
  • N. Nakahata
  • Biology, Medicine
  • Pharmacology & therapeutics
  • 2008
TLDR
Thromboxane A(2) (TXA(2), an unstable arachidonic acid metabolite, elicits diverse physiological/pathophysiological actions, including platelet aggregation and smooth muscle contraction, and several drugs modify TP-mediated events. Expand
Thromboxane A2 and related prostaglandins in airways
TLDR
Asthma is now thought to be a chronic inflammatory disease of the airways, and the recent development of specific and potent TP receptor antagonists and inhibitors of thromboxane synthase has provided tools to assess the role of TXA2 and bronchoconstrictor PGs in the pathophysiology of asthma. Expand
Advances in Brief Thromboxane A 2 Is a Mediator of Cyclooxygenase-2-dependent Endothelial Migration and Angiogenesis 1
Cyclooxygenase-2 (COX-2) inhibitors reduce angiogenic responses to a variety of stimuli, suggesting that products of COX-2 may mediate critical steps. Here, we show that thromboxane A 2 (TXA 2) isExpand
Cell signalling through thromboxane A2 receptors.
TLDR
Thromboxane A2 receptors have been shown to result in a broad range of cellular responses including phosphoinositide metabolism, calcium redistribution, cytoskeletal arrangement, integrin activation, kinase activation, and the subsequent nuclear signalling events involved in DNA synthesis, cell proliferation, cell survival and cell death. Expand
Arachidonic Acid in Cell Signaling
  • D. Piomelli
  • Medicine
  • Molecular Biology Intelligence Unit
  • 1996
TLDR
Cloning of the first eicosanoid receptors is a major step towards elucidating the diverse cellular functions exerted by these bioactive lipids. Expand
Solution structure of the third extracellular loop of human thromboxane A2 receptor.
TLDR
A peptide with the sequence of the third extracellular loop (eLP3, residues 271-289) of the TP receptor was synthesized, and its termini were constrained by the formation of a disulfide bond between the additional homocysteines located at both ends, providing valuable information for the characterization of the complete 3D structure of theextracellular domains of the human TP receptor. Expand
A thromboxane A(2) system in the Atlantic stingray, Dasyatis sabina.
TLDR
Northern blotting of mRNA isolated from the stingray kidney identified transcripts of 2.8 and 6kb, indicating the presence of a TXB(2)-like substance in the blood, a TP receptor in the kidney, TXA(2) biological activity in the ventral aorta, and expression of a TP receptors-like gene. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 55 REFERENCES
PROSTAGLANDINS AND THROMBOXANES
Publisher Summary There is now a better understanding of the physiological role of prostaglandins. Major significance has been the discovery that aspirin, indoinethacin and other non-steroidExpand
Gastroprotective effects of thromboxane receptor antagonists.
The recent discovery of potent, specific, long-acting thromboxane receptor antagonists, like SQ 33,961, mandated that studies be conducted to follow up an earlier study, which showed potentialExpand
Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders.
TLDR
Why these drugs can be more efficacious than traditional antiplatelet agents is explained here and the available experimental studies involving these drugs are reviewed. Expand
Antiplatelet agents in the prevention and therapy of thrombosis.
  • B. Coller
  • Medicine
  • Annual review of medicine
  • 1992
TLDR
Advances in understanding of platelet physiology provide crucial information for the rational design of newer agents that can neutralize thrombin and block the platelet receptor most important in platelet aggregation (GPIIb/IIIa). Expand
Regulation of thromboxane receptor activation in human platelets.
  • R. Murray, G. FitzGerald
  • Chemistry, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 1989
TLDR
Exposure of platelets to TxA2 receptor agonists results in rapid desensitization of the biochemical and functional responses to interaction with its receptor in human platelets, consistent with the hypothesis that this icosanoid functions in the regulation as well as amplification of platelet activation in vivo. Expand
Ligand binding to thromboxane receptors on human platelets: correlation with biological activity
1 The preparation of enantiomerically pure [3H]‐15 (S) 9, 11‐epoxymethano PGH2 (a thromboxane A2‐like agonist) has enabled the binding of ligands to the thromboxane receptor of the human platelet toExpand
Heterogeneity of thromboxane A2 (TP‐) receptors: evidence from antagonist but not agonist potency measurements
TLDR
The excellent agreement for both full and partial agonist potencies between the six preparations provides no evidence for TP‐receptor subtypes and further suggests that the agonist recognition sites of the TP‐ receptors could be very similar, if not identical, in nature. Expand
Characteristics of the binding of [3H]‐GR32191 to the thromboxane (TP‐) receptor of human platelets
TLDR
The interaction of [3H]‐GR32191 with human intact platelets was complex but the data were consistent with an action at a single class of binding site; from competition experiments this appears to be the functional TP‐receptor. Expand
Octimibate, a potent non‐prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor
TLDR
The aim of this study was to investigate the mechanism of the antithrombotic effect of octimibate, and to determine whether the effects of octIMibate are mediated through prostacyclin receptors. Expand
Competitive antagonism at thromboxane receptors in human platelets
TLDR
The block of the aggregatory action of 11,9‐epoxymethano‐PGH2 by PTA2 appears to be mainly due to competition at the thromboxane receptor, and the validity of affinity constant determinations for receptor antagonists when aggregation is the biological response. Expand
...
1
2
3
4
5
...